Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin plus metformin XR as initial combination therapy in type 2 diabetes
2011-000400-17Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canagliflozin and metformin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in glycated hemoglobin (HbA1c) from baseline to Week 26. Started May 2013; status: completed.
02
Drugs
canagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-000400-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000400-17.